Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02890329
Title Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Decitabine + Ipilimumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
UC San Diego Moores Cancer Center La Jolla California 92093 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Northside Hospital Atlanta Georgia 30342 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 United States Details
Brigham and Women's Hospital Boston Massachusetts 02115 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Case Western Reserve University Cleveland Ohio 44106 United States Details
University of Virginia Cancer Center Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field